pentoxifylline and rifaximin

PreclinicalSmall molecule

IInstitute of Liver and Biliary Sciences, India

pentoxifylline and rifaximin is one of 8 small molecule programs targeting Hepatopulmonary Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatopulmonary SyndromeActive, not recruiting

Hepatopulmonary SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Hepatopulmonary Syndrome

#DrugCompanyPhaseTrials

Nexavar

Bayer

Phase 2

1 2

Femara

Novartis

Phase 2

1 3

Tracleer

Johnson & Johnson

Phase 2

1 4

Chibroxin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 5

Proamatine

Takeda

Phase 1

1 6

Trental

VValidus Pharmaceuticals

Preclinical

2 7

Zocor

OOrganon and Co

Preclinical

1 8

pentoxifylline and rifaximin

IInstitute of Liver and Biliary Sciences, India

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatopulmonary Syndrome1 trial

Efficacy of Pentoxifylline and Rifaximin Combination in Pentoxifylline Refractory Clinical and Subclinical Hepatopulmonary Syndrome

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT01676597·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for pentoxifylline and rifaximin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pentoxifylline and rifaximin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pentoxifylline and rifaximin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Liver and Biliary Sciences, India company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInstitute of Liver and Biliary Sciences, India

pentoxifylline and rifaximin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatopulmonary Syndrome1 trial

References

Drug Info

Quick Facts

Related News